Integrated Manufacturing Leverage integrated manufacturing to de-risk gene therapy supply chains. MeiraGTx offers in-house plasmid GMP, two viral vector facilities, and a quality control hub designed for IND through commercial supply, enabling clients to outsource end-to-end manufacturing and reduce vendor fragmentation.

Late Stage Momentum Access late stage development and regulatory momentum. With a pipeline nearing potential approvals and a FDA Breakthrough Therapy designation, MeiraGTx can partner on co development, manufacturing scale up, and potential commercialization, accelerating time to market for partners assets.

Riboswitch Collaboration Explore riboswitch collaboration for nontraditional modalities. The dose responsive gene regulation platform delivered via oral small molecules can unlock metabolic peptide delivery and cell therapies; opportunities exist for joint development, licensing, or early stage manufacturing access for assets leveraging this platform.

Financially Ready Partnerships Financial readiness enables ambitious partnerships. A strengthened balance sheet and recent financing provide capital to fund manufacturing scale up, milestone driven deals, and upfront support for partners programs, improving terms for long term supply agreements.

Global Therapeutic Focus Global reach with therapeutic focus. Based in London with ophthalmology CNS and salivary gland expertise and plans to apply to broader diseases, MeiraGTx can support cross border programs and global supply, offering regional market access and regulatory familiarity alongside its manufacturing footprint.